Disproportionate Burden of Cardiovascular-Kidney-Metabolic Factors in Patients with Adverse SDOH
November 15th 2023Session speaker Powell-Wiley explains how screening for SDOH in patients as cardiovascular-kidney-metabolic syndrome stages progress can help better understand their individual social needs.
Read More
Amivantamab With Lazertinib Can Reduce Risk of Disease Progression By 30% in Patients With NSCLC
October 25th 2023Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.
Read More
Nivolumab Plus Chemotherapy Treatment Followed By Surgery Improved EFS in Patients With NSCLC
October 25th 2023Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.
Read More